门冬胰岛素与生物合成人胰岛素分别联合甘精胰岛素治疗2型糖尿病的临床比较分析
 |
| 第1页 |
参见附件。
【摘要】目的:研究和分析门冬胰岛素与生物合成人胰岛素粉笔与甘精胰岛素治疗2型糖尿病的临床效果以及用药后病人的身体情况，从而探讨临床上应该如何应用。方法：抽取2型糖尿病患者72例随机分为观察组和对照组,观察两组在治疗前和治疗后以及用餐后的2h-PPG、FPG、达标时间及低血糖发生次数等。结果：观察组和对照组从患者开始用药前到用药后，2h-PPG、FPG无明显差异(P<0.01)。结论：门冬胰岛素联合甘精胰岛素或者生物合成人胰岛素联合甘精胰岛素，在临床上并无差异。但是配伍甘精胰岛素发生低血糖发生次数少，用量小，血糖达标稳定，效果作用性强，非常值得临床推广。
【关键词】门冬胰岛素；生物合成人胰岛素；联合甘精胰岛素；2型糖尿病
Comparative analysis of aspart insulin and biosynthetic human insulin combined with insulin glargine clinical treatment of type 2 diabetes
Pang hong
Petroleum Hospital of Suining City,Sichuan Province,Suining 629000,China
[Abstract] Objective: To research and analysis of insulin aspart and biosynthetic human insulin chalk and insulin glargine in type 2 diabetes clinical effect and the drug after the patient's physical condition, so as to explore how clinical application. Methods: The extract in patients with type 2 diabetes, 72 cases were randomly divided into observation group and control group were observed before treatment and after treatment, as well as the number of 2h-PPG, FPG and the standard time and low blood sugar after a meal. Results: The observation group and control group from the patients before treatment to after treatment, the 2h-of PPG of FPG was no significant difference (P <0.01). Conclusion: insulin aspart joint glargine insulin or biosynthetic human insulin joint glargine insulin, there was no difference in the clinical Compatibility of insulin glargine hypoglycemia occurred fewer, small amount of blood glucose is stable, the effect of the role of strong, very worthy of promotion.
Key words: insulin aspart; biosynthetic human insulin; joint glargine; type 2 diabetes
2型糖尿病的主要致病原理是胰岛素于是开始存在抵抗高胰岛素血症，并且随着病程延长，胰岛功能开始下降，必须服用胰岛素进行治疗[1]。一般的口服药物根本没有办法达到良好的治疗效果 ......
您现在查看是摘要介绍页，详见PDF附件(2217kb)。